BMJ4d
Impact of the COVID-19 pandemic on incidence of coronary heart disease in Bavaria, Germany: an analysis of health claims data
Background Inconsistent findings about the impact of the COVID-19 pandemic on cardiovascular disease diagnosis and ...
BMJ4d
Industry marketing payments to physicians and prescription patterns for sacubitril/valsartan in the USA
Objectives Although financial interactions between physicians and pharmaceutical and medical device companies could be ...
BMJ10d
Optimising management of moderate secondary mitral regurgitation: insights into pharmacological and interventional approaches
Secondary mitral regurgitation (SMR) is a complex and evolving challenge in the landscape of heart failure (HF) management. Although significant secondary MR has been widely recognised for its adverse ...
BMJ10d
Atrial arrhythmia and heart failure in adult patients with congenital heart disease: a retrospective cohort study
Background Atrial arrhythmias (AA) and heart failure (HF) are major causes of hospitalisation in adult congenital heart disease (ACHD). This study aimed to evaluate the temporal relationship between ...
BMJ22h
Interface between valve disease and ischaemic heart disease
Dr Bernard Iung, Cardiology Department, Bichat Hospital, 46, rue Henri Huchard, 75018 Paris, France email: bernard.iung{at}bch.ap-hop-paris.fr If you wish to reuse ...
BMJ6d
Successful transcatheter aortic valve implantation (TAVI) is associated with transient left ventricular dysfunction
King's College London BHF Centre of Excellence, Department of Cardiology, King's College Hospital, London, UK Correspondence to Dr Philip MacCarthy, Consultant Cardiologist, Department of Cardiology, ...
BMJ12d
Excessive daytime sleepiness: an emerging marker of cardiovascular risk
Excessive daytime sleepiness (EDS) is classically viewed as a consequence of insufficient sleep or a symptom of sleep disorders. Epidemiological and clinical evidence have shown that patients ...
BMJ10d
Timing of intervention in aortic stenosis: a review of current and future strategies
Correspondence to Dr Russell James Everett, BHF/Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4SB, UK; russell.everett{at}ed.ac.uk To review the pathophysiology of ...
BMJ6d
Mental disorders and cardiovascular disease: what should we be looking out for?
Correspondence to Dr Matthias Michal, Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz 55131, Germany; ...
BMJ11d
Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial
Background To determine whether granulocyte colony-stimulating factor (G-CSF) improves clinical outcomes after large ST-elevation myocardial infarction (STEMI) when administered early in patients with ...
BMJ12d
Aspirin: latest evidence and developments
Aspirin is a foundation drug of the pharmaceutical industry originally derived as an analgesic/anti-inflammatory agent but serendipitously discovered to have use as a prophylactic drug for major ...
BMJ7d
Percutaneous coronary intervention for stable coronary artery disease
The adverse consequences of stable coronary artery disease (CAD) are death, myocardial infarction (MI) and angina. Trials in stable CAD show that percutaneous coronary intervention (PCI) does not ...